Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.17 USD
+0.14 (1.07%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $13.17 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value F Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4,097 | 7,788 | 9,427 | 6,012 |
Receivables | NA | 5,045 | 6,447 | 7,640 | 7,221 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 7,300 | 7,593 | 7,086 | 6,988 |
Other Current Assets | NA | 1,303 | 1,256 | 1,349 | 2,498 |
Total Current Assets | NA | 17,745 | 23,083 | 25,501 | 22,719 |
Net Property & Equipment | NA | 12,515 | 14,087 | 13,667 | 12,755 |
Investments & Advances | NA | 2,804 | 2,938 | 3,274 | 3,399 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 2,708 | 3,227 | 3,325 | 2,835 |
Intangibles | NA | 67,047 | 73,214 | 74,664 | 75,292 |
Deposits & Other Assets | NA | 469 | 735 | 943 | 955 |
Total Assets | NA | 103,287 | 117,284 | 121,376 | 117,954 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4,804 | 4,595 | 3,232 | 2,933 |
Current Portion Long-Term Debt | NA | 2,513 | 1,816 | 208 | 5,399 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 1,720 | 1,788 | 1,365 | 1,681 |
Other Current Liabilities | NA | 9,329 | 10,898 | 11,863 | 10,005 |
Total Current Liabilities | NA | 18,366 | 19,097 | 16,668 | 20,018 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 2,003 | 4,018 | 5,103 | 6,533 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 29,916 | 36,859 | 43,364 | 41,460 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 5,978 | 6,727 | 7,575 | 6,450 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 56,263 | 66,701 | 72,710 | 74,461 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 12,405 | 14,919 | 15,681 | 15,347 |
Capital Surplus | NA | 12,793 | 15,209 | 15,871 | 15,459 |
Retained Earnings | NA | 11,404 | 13,169 | 14,193 | 12,604 |
Other Equity | NA | 11,164 | 8,319 | 3,480 | 888 |
Treasury Stock | NA | 742 | 1,032 | 560 | 805 |
Total Shareholder's Equity | NA | 47,025 | 50,583 | 48,665 | 43,493 |
Total Liabilities & Shareholder's Equity | NA | 103,287 | 117,284 | 121,376 | 117,954 |
Total Common Equity | 0 | 47,025 | 50,583 | 48,665 | 43,493 |
Shares Outstanding | 3,164.80 | 3,164.50 | 3,100.70 | 3,155.70 | 3,152.70 |
Book Value Per Share | 0.00 | 14.86 | 16.31 | 15.42 | 13.80 |
Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 2,158 | 2,303 | 2,691 | 4,097 |
Receivables | NA | 5,053 | 5,438 | 6,026 | 5,045 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 7,954 | 7,975 | 7,909 | 7,300 |
Other Current Assets | NA | 1,351 | 1,272 | 1,420 | 1,303 |
Total Current Assets | NA | 16,516 | 16,988 | 18,046 | 17,745 |
Net Property & Equipment | NA | 12,522 | 13,070 | 13,106 | 12,515 |
Investments & Advances | NA | 2,536 | 2,873 | 2,873 | 2,804 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 2,153 | 2,320 | 2,741 | 2,708 |
Intangibles | NA | 62,617 | 66,954 | 70,782 | 67,047 |
Deposits & Other Assets | NA | 372 | 412 | 439 | 469 |
Total Assets | NA | 96,716 | 102,616 | 107,987 | 103,287 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3,289 | 2,905 | 3,219 | 4,804 |
Current Portion Long-Term Debt | NA | 2,518 | 1,896 | 3,043 | 2,513 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 765 | 899 | 1,772 | 1,720 |
Other Current Liabilities | NA | 8,947 | 10,636 | 10,229 | 9,329 |
Total Current Liabilities | NA | 15,519 | 16,337 | 18,263 | 18,366 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 905 | 1,578 | 1,968 | 2,003 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 29,198 | 30,390 | 31,611 | 29,916 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 5,521 | 5,618 | 5,978 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 50,866 | 53,826 | 57,459 | 56,263 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 11,400 | 11,568 | 12,238 | 12,405 |
Capital Surplus | NA | 11,765 | 11,807 | 12,716 | 12,793 |
Retained Earnings | NA | 9,499 | 9,978 | 10,878 | 11,404 |
Other Equity | NA | 13,534 | 15,792 | 15,428 | 11,164 |
Treasury Stock | NA | 349 | 354 | 732 | 742 |
Total Shareholder's Equity | NA | 45,850 | 48,790 | 50,528 | 47,025 |
Total Liabilities & Shareholder's Equity | NA | 96,716 | 102,616 | 107,987 | 103,287 |
Total Common Equity | 0 | 45,850 | 48,790 | 50,528 | 47,025 |
Shares Outstanding | 3,164.80 | 3,164.70 | 3,164.70 | 3,164.60 | 3,164.50 |
Book Value Per Share | 0.00 | 14.49 | 15.42 | 15.97 | 14.86 |